Bevacizumab and breast cancer: The E2100 outlier

The Lancet Oncology

Volumn 11, Issue 12, 2010, Pages 1117-1119

  Fojo, Tito ^a   Wilkerson, Julia ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PACLITAXEL; VASCULOTROPIN;

BREAST CANCER; CORRELATION ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; GENE LOCUS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; METASTASIS POTENTIAL; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; TREATMENT RESPONSE; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; PACLITAXEL;

EID: 78649586869     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70259-X     Document Type: Note

References (11)

1. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
2. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247.
3. Robert N, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 10-13, 2009. Abstract 6084.
4. Chan A, Miles DW, Pivot X Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Ann Oncol 2010, published online March 24, 2010. 10.1093/annonc/mdq122.
5. O'Shaughnessy J, Dieras V, Glaspy J, et al. Comparison of subgroup analyses of PFS from three phase III studies of bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium; San Antonio, TX, USA; Dec 10-13, 2009. Absract 207.
6. National Cancer Institute, (accessed Nov 10, 2010). http://www.cancer.gov/ncicancerbulletin/072710/page2.
7. Lebwohl D, Kay A, Berg W, Baladi JF, Zheng J Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J 2009, 15:386-394.
8. Zhuang SH, Xiu L, Elsayed YA Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy. Cancer J 2009, 15:395-400.
9. Wilkerson J, Fojo T Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. Cancer J 2009, 15:379-385.
10. Vidaurre T, Wilkerson J, Simon R, Bates SE, Fojo T Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development. Cancer J 2009, 15:366-373.
11. Schneider BP, Wang M, Radovich M Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008, 26:4672-4678. for the ECOG 2100.